Literature DB >> 14660646

Recovery from DNA damage-induced G2 arrest requires actin-binding protein filamin-A/actin-binding protein 280.

Xiangbing Meng1, Yuan Yuan, Adrian Maestas, Zhiyuan Shen.   

Abstract

Filamin-A (filamin-1) is an actin-binding protein involved in the organization of actin networks. Our previous study shows that filamin-A interacts with BRCA2, and lack of filamin-A expression results in increased cellular sensitivity to several DNA damaging agents in melanoma cells (Yuan, Y., and Shen, Z. (2001) J. Biol. Chem. 276, 48318-48324), suggesting a role of filamin-A in DNA damage response. In this report, we demonstrated that deficiency of filamin-A results in an 8-h delay in the recovery from G2 arrest in response to ionizing radiation. However, filamin-A deficiency does not affect the initial activation of the G2/M checkpoint. We also found that filamin-A deficiency results in sustained activation of Chk1 and Chk2 after irradiation. This in turn causes a delay in the dephosphorylation of phospho-Cdc2, which is inhibitory to the G2/M transition. In addition, filamin-A-deficient M2 cells undergo mitotic catastrophe-related nuclear fragmentation after they are released from the G2 arrest. Together, these data suggest a functional role of filamin-A in the recovery from G2 arrest and subsequent mitotic cell death after DNA damage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14660646     DOI: 10.1074/jbc.M306794200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  Ultrastructural localization of actin and actin-binding proteins in the nucleus.

Authors:  Hana Dingová; Jana Fukalová; Miloslava Maninová; Vlada V Philimonenko; Pavel Hozák
Journal:  Histochem Cell Biol       Date:  2008-11-28       Impact factor: 4.304

2.  The BRCA2-interacting protein BCCIP functions in RAD51 and BRCA2 focus formation and homologous recombinational repair.

Authors:  Huimei Lu; Xu Guo; Xiangbing Meng; Jingmei Liu; Chris Allen; Justin Wray; Jac A Nickoloff; Zhiyuan Shen
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

3.  Functions of nuclear actin-binding proteins in human cancer.

Authors:  Xinyi Yang; Ying Lin
Journal:  Oncol Lett       Date:  2017-12-19       Impact factor: 2.967

4.  Adapter protein SH2B1beta binds filamin A to regulate prolactin-dependent cytoskeletal reorganization and cell motility.

Authors:  Leah Rider; Maria Diakonova
Journal:  Mol Endocrinol       Date:  2011-05-12

5.  Filamin-A as a marker and target for DNA damage based cancer therapy.

Authors:  Jingyin Yue; Huimei Lu; Jingmei Liu; Marianne Berwick; Zhiyuan Shen
Journal:  DNA Repair (Amst)       Date:  2011-11-02

6.  Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity.

Authors:  Letizia Porcelli; Anna E Quatrale; Paola Mantuano; Maria G Leo; Nicola Silvestris; Jean F Rolland; Enza Carioggia; Marco Lioce; Angelo Paradiso; Amalia Azzariti
Journal:  Mol Oncol       Date:  2012-10-29       Impact factor: 6.603

7.  The role of FilGAP-filamin A interactions in mechanoprotection.

Authors:  Yulia Shifrin; Pamela D Arora; Yasutaka Ohta; David A Calderwood; Christopher A McCulloch
Journal:  Mol Biol Cell       Date:  2009-01-14       Impact factor: 4.138

8.  Filamin A is required for vimentin-mediated cell adhesion and spreading.

Authors:  Hugh Kim; Fumihiko Nakamura; Wilson Lee; Yulia Shifrin; Pamela Arora; Christopher A McCulloch
Journal:  Am J Physiol Cell Physiol       Date:  2009-09-23       Impact factor: 4.249

9.  Filamin A modulates kinase activation and intracellular trafficking of epidermal growth factor receptors in human melanoma cells.

Authors:  Jennifer L Fiori; Tie-Nian Zhu; Michael P O'Connell; Keith S Hoek; Fred E Indig; Brittany P Frank; Christa Morris; Sutapa Kole; Joanne Hasskamp; George Elias; Ashani T Weeraratna; Michel Bernier
Journal:  Endocrinology       Date:  2009-02-12       Impact factor: 4.736

10.  Roles of BCCIP in chromosome stability and cytokinesis.

Authors:  X Meng; J Fan; Z Shen
Journal:  Oncogene       Date:  2007-04-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.